Future G protein-coupled receptor targets for treatment of heart failure

Giuseppe Rengo, Anastasios Lymperopoulos, Walter J. Koch

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Heart failure (HF) still poses an enormous clinical challenge, as its incidence, morbidity, and mortality rates are continuously rising. G protein-coupled receptors (GPCRs) constitute the most ubiquitous superfamily of plasma membrane receptors and represent the single most important type of therapeutic drug target. Because there is overstimulation of the failing heart by various endogenous ligands, such as catecholamines and angiotensin II - which by activating their cognate GPCRs in cardiac muscle induce detrimental effects - therapeutic targeting of these receptors has been pursued. This research has led to the development of successful and useful drug classes, such as angiotensin-converting enzyme inhibitors and α-adrenergic receptor blockers. However, there still is a need to develop innovative treatments that might be more effective at reversing compromised myocyte function. Over the past several years, much evidence has accumulated indicating that a single GPCR, activated by the same endogenous ligand, can elicit several different signaling pathways with quite different, and often opposite, cellular effects. Because the aforementioned ligands, currently used for HF, target these receptors on their extracellular interface, thus merely preventing the endogenous agonists from binding the receptor, they inhibit all the signaling pathways elicited by the receptor indiscriminately. Importantly, several of these pathways emanating from the same GPCR can actually be beneficial for therapy, so their enhancement rather than their blockade is desirable for HF therapy. This highlights the need for selective targeting of GPCR-induced signaling pathways on the intracellular interface of the receptor, which might produce new and innovative therapies for cardiovascular disease.

Original languageEnglish
Pages (from-to)328-338
Number of pages11
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume11
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

G-Protein-Coupled Receptors
Treatment Failure
Heart Failure
Ligands
Investigational Therapies
Adrenergic Antagonists
Therapeutic Uses
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Pharmaceutical Preparations
Adrenergic Receptors
Muscle Cells
Catecholamines
Myocardium
Cardiovascular Diseases
Cell Membrane
Morbidity
Mortality
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Future G protein-coupled receptor targets for treatment of heart failure. / Rengo, Giuseppe; Lymperopoulos, Anastasios; Koch, Walter J.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 11, No. 4, 2009, p. 328-338.

Research output: Contribution to journalArticle

@article{89d01fcfeae64298829f6227d708bd69,
title = "Future G protein-coupled receptor targets for treatment of heart failure",
abstract = "Heart failure (HF) still poses an enormous clinical challenge, as its incidence, morbidity, and mortality rates are continuously rising. G protein-coupled receptors (GPCRs) constitute the most ubiquitous superfamily of plasma membrane receptors and represent the single most important type of therapeutic drug target. Because there is overstimulation of the failing heart by various endogenous ligands, such as catecholamines and angiotensin II - which by activating their cognate GPCRs in cardiac muscle induce detrimental effects - therapeutic targeting of these receptors has been pursued. This research has led to the development of successful and useful drug classes, such as angiotensin-converting enzyme inhibitors and α-adrenergic receptor blockers. However, there still is a need to develop innovative treatments that might be more effective at reversing compromised myocyte function. Over the past several years, much evidence has accumulated indicating that a single GPCR, activated by the same endogenous ligand, can elicit several different signaling pathways with quite different, and often opposite, cellular effects. Because the aforementioned ligands, currently used for HF, target these receptors on their extracellular interface, thus merely preventing the endogenous agonists from binding the receptor, they inhibit all the signaling pathways elicited by the receptor indiscriminately. Importantly, several of these pathways emanating from the same GPCR can actually be beneficial for therapy, so their enhancement rather than their blockade is desirable for HF therapy. This highlights the need for selective targeting of GPCR-induced signaling pathways on the intracellular interface of the receptor, which might produce new and innovative therapies for cardiovascular disease.",
author = "Giuseppe Rengo and Anastasios Lymperopoulos and Koch, {Walter J.}",
year = "2009",
doi = "10.1007/s11936-009-0033-5",
language = "English",
volume = "11",
pages = "328--338",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Future G protein-coupled receptor targets for treatment of heart failure

AU - Rengo, Giuseppe

AU - Lymperopoulos, Anastasios

AU - Koch, Walter J.

PY - 2009

Y1 - 2009

N2 - Heart failure (HF) still poses an enormous clinical challenge, as its incidence, morbidity, and mortality rates are continuously rising. G protein-coupled receptors (GPCRs) constitute the most ubiquitous superfamily of plasma membrane receptors and represent the single most important type of therapeutic drug target. Because there is overstimulation of the failing heart by various endogenous ligands, such as catecholamines and angiotensin II - which by activating their cognate GPCRs in cardiac muscle induce detrimental effects - therapeutic targeting of these receptors has been pursued. This research has led to the development of successful and useful drug classes, such as angiotensin-converting enzyme inhibitors and α-adrenergic receptor blockers. However, there still is a need to develop innovative treatments that might be more effective at reversing compromised myocyte function. Over the past several years, much evidence has accumulated indicating that a single GPCR, activated by the same endogenous ligand, can elicit several different signaling pathways with quite different, and often opposite, cellular effects. Because the aforementioned ligands, currently used for HF, target these receptors on their extracellular interface, thus merely preventing the endogenous agonists from binding the receptor, they inhibit all the signaling pathways elicited by the receptor indiscriminately. Importantly, several of these pathways emanating from the same GPCR can actually be beneficial for therapy, so their enhancement rather than their blockade is desirable for HF therapy. This highlights the need for selective targeting of GPCR-induced signaling pathways on the intracellular interface of the receptor, which might produce new and innovative therapies for cardiovascular disease.

AB - Heart failure (HF) still poses an enormous clinical challenge, as its incidence, morbidity, and mortality rates are continuously rising. G protein-coupled receptors (GPCRs) constitute the most ubiquitous superfamily of plasma membrane receptors and represent the single most important type of therapeutic drug target. Because there is overstimulation of the failing heart by various endogenous ligands, such as catecholamines and angiotensin II - which by activating their cognate GPCRs in cardiac muscle induce detrimental effects - therapeutic targeting of these receptors has been pursued. This research has led to the development of successful and useful drug classes, such as angiotensin-converting enzyme inhibitors and α-adrenergic receptor blockers. However, there still is a need to develop innovative treatments that might be more effective at reversing compromised myocyte function. Over the past several years, much evidence has accumulated indicating that a single GPCR, activated by the same endogenous ligand, can elicit several different signaling pathways with quite different, and often opposite, cellular effects. Because the aforementioned ligands, currently used for HF, target these receptors on their extracellular interface, thus merely preventing the endogenous agonists from binding the receptor, they inhibit all the signaling pathways elicited by the receptor indiscriminately. Importantly, several of these pathways emanating from the same GPCR can actually be beneficial for therapy, so their enhancement rather than their blockade is desirable for HF therapy. This highlights the need for selective targeting of GPCR-induced signaling pathways on the intracellular interface of the receptor, which might produce new and innovative therapies for cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=67651113673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651113673&partnerID=8YFLogxK

U2 - 10.1007/s11936-009-0033-5

DO - 10.1007/s11936-009-0033-5

M3 - Article

VL - 11

SP - 328

EP - 338

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 4

ER -